WO2007012809A2 - Improvements relating to the detection of lower limb disease - Google Patents

Improvements relating to the detection of lower limb disease Download PDF

Info

Publication number
WO2007012809A2
WO2007012809A2 PCT/GB2006/002626 GB2006002626W WO2007012809A2 WO 2007012809 A2 WO2007012809 A2 WO 2007012809A2 GB 2006002626 W GB2006002626 W GB 2006002626W WO 2007012809 A2 WO2007012809 A2 WO 2007012809A2
Authority
WO
WIPO (PCT)
Prior art keywords
disease
limb
doppler
waveform
peripheral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2006/002626
Other languages
French (fr)
Other versions
WO2007012809A3 (en
Inventor
Dean Williams
Keith Gordon Harding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Cardiff University
Original Assignee
University College Cardiff Consultants Ltd
Cardiff University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd, Cardiff University filed Critical University College Cardiff Consultants Ltd
Publication of WO2007012809A2 publication Critical patent/WO2007012809A2/en
Publication of WO2007012809A3 publication Critical patent/WO2007012809A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/06Measuring blood flow

Definitions

  • the invention relates to a method for detecting peripheral limb disease and, in particular, lower limb disease which is, typically, common in individuals suffering from diabetes. Further, the invention relates to the use of waveform instrumentation, and in particular a hand held for device for use in the aforementioned method.
  • Foot related disease is the most common cause for hospital admission amongst the diabetic population and is recognised as the most common cause of non-traumatic lower limb amputation in the western world. People with diabetes are over 20 times more likely to undergo an amputation compared to the rest of the population (1) and since this population is growing it is placing increasing demands on healthcare provision.
  • the main risk factors in the development of diabetic foot disease are peripheral neuropathy and peripheral arterial occlusive disease.
  • the detection of significant arterial disease is vital to the prevention and treatment of foot disease.
  • the unreliable nature of the symptoms and signs of lower limb arterial insufficiency in diabetes means that non-invasive tests are essential to achieve effective screening (2,3).
  • the European Working Group on critical leg ischaemia recommends an additional, non-invasive vascular assessment for patients with diabetes and foot ulceration (4).
  • ABPI Ankle-brachial pressure index
  • TBI Toe-brachial pressure index
  • a method for screening for peripheral limb disease comprising: a) exposing vascular peripheral tissue to a selected wave energy and performing Doppler analysis thereon in order to generate data indicative of the nature of fluid flow in, or through, said vascular tissue; b) examining said data for reverse flow or loss of triphasic signal; and c) where said loss of reverse flow or loss of triphasic signal is present concluding that there is disease in said limb.
  • a method for screening for peripheral limb disease comprising: exposing vascular peripheral tissue to a selected wave energy and performing Doppler analysis thereon in order to determine the nature of fluid flow in, or through, said vascular tissue whereby an indicator showing loss of reverse flow or loss of triphasic signal is indicative of disease in said limb.
  • the peripheral limb is a lower limb such as a foot and, more preferably still, the indicator is indicative of arterial disease in said limb.
  • Doppler analysis can be undertaken in either a qualitative or quantitative fashion.
  • visual interpretation of an image of a waveform, representing blood flow in said tissue i.e. an image showing forward and, if present, reverse flow, can be used to judge the nature of the flow in, or through, said vascular tissue.
  • the said waveform may be undertaken.
  • at least one index of said waveform is analysed such as, without limitation, the pulsatility index, resistance index or specteral broadening index may be used.
  • the monophasic, biphasic or triphasic profiles of said vascular tissue Reference herein to monophasic, biphasic or triphasic profiles includes reference to the waveforms described in reference 13 wherein a monophasic profile (or waveform) is indicative of a single forward flow, a biphasic profile (or waveform) is indicative of 2 forward flows and a triphasic profile (or waveform) is indicative of a forward, reverse, forward flow. These waveforms are further illustrated in Figure 1.
  • said selected wave energy is ultrasound and most preferably at a frequency between 3 and 10 MHz and most typically at a frequency of between 5 and 8 MHz.
  • an apparatus for use in determining peripheral limb disease comprising: a Doppler waveform generating device which can be applied to a limb to be investigated, or held in close proximity thereto, in order to generate Doppler information relating to fluid flow in said limb; and a display device to which said Doppler waveform generating device is operationally coupled, said display device including an image generating device whereby visual images produced by said image generating device of waveforms produced by said Doppler generating device can be displayed for the purpose of enabling at least qualitative analysis thereof.
  • a device most preferably a hand-held device, for use in determining peripheral limb disease, wherein said device comprises a hand held Doppler waveform device operationally coupled to a display device whereby visual images of waveforms produced by said device are displayed in conventional manner, on said display device for the purpose of enabling at least qualitative analysis thereof by a user.
  • a hand-held Doppler analysis device can be routinely and reliably used in order to determine peripheral limb disease, and, more specifically, lower limb or foot disease in diabetes where more preferably, the device is used to determine arterial disease in diabetes.
  • this existing piece of equipment is operationally coupled to a display device or screen whereby at least a qualitative assessment of visual images representing waveforms of fluid flow in peripheral limbs can be made.
  • Figure 1 is a diagram showing the characteristics of monophasic, biphasic and triphasic flow patterns through peripheral limb tissue;
  • Figure 2 represents a chart showing the ABPI index for a variety of subjects. Horizontal lines represent ABPI values of 1.15 and 0.9.
  • V represents the control subjects with arterial disease; D represents diabetics; DN represents diabetics with neuropathy; C represents control subjects; DV represents diabetics with arterial disease; DNV represents diabetics with neuropathy and arterial disease;
  • Figure 3 shows the ABPI and TBI indices for a variety of subjects. Horizontal lines represent an ABPI value of 0.9 and a TBI value of 0.75.
  • V represents control subjects with arterial disease; D represents diabetics; DN represents diabetics with neuropathy; C represents control subjects; DV represents diabetics with arterial disease; DNV represents diabetics with neuropathy and arterial disease.
  • Figure 4 is a diagrammatic representation of a hand held Doppler device adapted for use in accordance with the invention. Parameters for the investigation
  • Exclusion criteria included smoking, other causes of peripheral neuropathy, history of reconstructive vascular surgery, other causes of peripheral vascular disease, skin changes associated with venous disease, pyrexia and significant cardiorespiratory and/or renal disease. All patients (with
  • Foot pulses of individuals with diabetes and/or peripheral vascular disease were palpated by at least two examiners and classified as present or absent. Absence of one or both foot pulses was used as an indicator of arterial disease.
  • Toe pressures were measured by the photplethysmographic (PPG) method, employing an infrared sensor placed on the hallux, (Dopplex Assist,
  • CDI was deemed significant when occlusions, single or multiple stenoses, or diffuse stenotic disease in the femoropopliteal segments, individually or collectively, caused significant velocity change and flow disturbance locally and resulted in loss of reverse flow distally. Occlusions of below-knee arteries were also recorded. Quality control was assured by acquiring a second CDI scan of
  • All groups with diabetes had mean body mass indices greater than 25, the group with neuropathy greater than 30.
  • the Resistance Index was the more accurate indicator of arterial disease than the Pulsatility or Spectral Broadening Indices.
  • this modality's major limitation in this study was its inability to perform accurate analyses in the presence of low amplitude and/or low intensity signals, often allocating normal index values to qualitatively abnormal waveforms. This was most evident in the group with diabetes and arterial disease, where 14 of 46 analyses (30%) were erroneous.
  • ABPI accurately reflected underlying arterial disease in the limbs of individuals without diabetes and those with diabetes but no detectable peripheral neuropathy.
  • ABPI demonstrated the highest specificity and positive predictor value of all the tests across all groups (Table 2), low values being highly indicative of arterial disease.
  • this inability to detect arterial disease in the presence of detectable peripheral neuropathy resulted in false negative results in 1/3 of limbs. This finding is probably due to the influence of arterial calcification.
  • ABPI was less sensitive than palpation of foot pulses in screening for arterial disease in diabetes in the presence of detectable peripheral neuropathy.
  • TBI did not improve on the screening offered by pulses and ABPI in limbs without neuropathy, but was superior to ABPI in screening for arterial disease in limbs with neuropathy, with a normal TBI effectively excluding the presence of significant arterial disease in limbs with neuropathy.
  • TBI maintained its sensitivity through all the diabetes groups. Its specificity did however reduce in the presence of peripheral neuropathy and this reflected in a reduced accuracy (Table 2).
  • TBI was demonstrated to be an effective screening tool in diabetes, both in limbs with and without detectable peripheral neuropathy and appears therefore to be less influenced by arterial calcification than ABPI.
  • Figure 4 shows a representation of a hand held Doppler device for use in the method of the invention.
  • the device comprises a Doppler Probe 1 , of conventional nature, which is operationally and releasably coupled to an audio/visual display means 2.
  • Display means 2 comprises a screen 3 and speaker 4.
  • Waveforms indicative of fluid or blood flow in tissue under examination are represented, in conventional manner and using conventional equipment, on screen 3 +/or via sounds emanating from speaker 4.
  • a user of the equipment is therefore able to use Doppler Probe 1 to visualise blood flow in selected tissue and using conventional skill and judgement perform a qualitative analysis of the images +/or sounds presented on screen 3 or emanating from speaker 4.
  • the invention can be straight forwardly practised by those skilled in the art with a view to efficiently and reliably diagnosing vascular disease, particularly in lower limbs.
  • Faglia E Favales F, Quarantiello A, Calia P, Clelia P, Brambilla G 1
  • Toursarkissian B Mejia A, Smilanich RP, Schoolfield J, Shireman PK,
  • Sykes MT Noninvasive localization on infrainguinal arterial occlusive disease in diabetics. Ann Vase Surg 15:73-78, 2001.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)

Abstract

The invention relates to a method for screening for peripheral limb disease comprising the use of Doppler sound to investigate the presence of reverse flow in peripheral blood vessels.

Description

IMPROVEMENTS RELATING TO THE DETECTION OF LOWER LIMB DISEASE
The invention relates to a method for detecting peripheral limb disease and, in particular, lower limb disease which is, typically, common in individuals suffering from diabetes. Further, the invention relates to the use of waveform instrumentation, and in particular a hand held for device for use in the aforementioned method.
Foot related disease is the most common cause for hospital admission amongst the diabetic population and is recognised as the most common cause of non-traumatic lower limb amputation in the western world. People with diabetes are over 20 times more likely to undergo an amputation compared to the rest of the population (1) and since this population is growing it is placing increasing demands on healthcare provision. The main risk factors in the development of diabetic foot disease are peripheral neuropathy and peripheral arterial occlusive disease. The detection of significant arterial disease is vital to the prevention and treatment of foot disease. The unreliable nature of the symptoms and signs of lower limb arterial insufficiency in diabetes means that non-invasive tests are essential to achieve effective screening (2,3). The European Working Group on critical leg ischaemia recommends an additional, non-invasive vascular assessment for patients with diabetes and foot ulceration (4).
Commonly employed screening techniques used in assessing lower limb perfusion are the palpation of foot pulses and calculation of the Ankle-brachial pressure index (ABPI) and/or Toe-brachial pressure index (TBI).
There is continued debate regarding the influence of peripheral neuropathy and arterial calcification on the reliability of vascular screening in diabetes. Calcification due to medial sclerosis secondary to autonomic neuropathy and calcified atherosclerotic plaques cause increased arterial rigidity, potentially making palpation of foot pulses more difficult and artificially elevating the ankle systolic blood pressure and ABPI measurement (5). The recent International Consensus on the Diabetic Foot (ICDF) guidelines suggested that an ABPI of 1.156 be the upper limit above which measurements are deemed unreliable (6). TBI is then an alternative test, but the influence of arterial calcification and neuropathy on toe pressures Is uncertain (7-11).
It can therefore be seen that there is a need to provide an alternative and more accurate method and means for the diagnosis, and more preferably, the early diagnosis of peripheral limb, and more particularly, foot related disease. Doppler waveform analysis is used in Colour Duplex Imaging (CDI) to grade the severity of arterial stenotic disease, but there is uncertainty regarding its accuracy when used alone in assessing the severity of lower limb arterial disease (12,13).
Despite this prejudice in the field, we decided to investigate the relevance of waveform analysis in determining peripheral limb disease and in particular lower limb arterial disease in diabetes. We have therefore aimed to evaluate the efficacy of using foot pulses, ABPI, TBI and Doppler waveform analysis in screening for lower limb arterial disease in diabetes.
As a result of our investigations we have found that contrary to uncertainties expressed by co-workers in the field waveform analysis can be used to predict peripheral limb disease and, moreover, is a more accurate predictor than existing techniques such as the palpation of foot pulses, the calculation of ankle-brachial pressure index (ABPI) and/or toe-brachial pressure index (TBI) - i.e. established techniques when used to screen for lower limb disorders.
Accordingly, we have identified a new method for evaluating tissue for the presence of disease and in particular vascular disease, which in this particular application is used for determining vascular disease in diabetes and, more especially, lower limb arterial disease in diabetes.
According to a first aspect of the invention there is provided a method for screening for peripheral limb disease comprising: a) exposing vascular peripheral tissue to a selected wave energy and performing Doppler analysis thereon in order to generate data indicative of the nature of fluid flow in, or through, said vascular tissue; b) examining said data for reverse flow or loss of triphasic signal; and c) where said loss of reverse flow or loss of triphasic signal is present concluding that there is disease in said limb.
According to an alternative aspect of the invention there is therefore provided a method for screening for peripheral limb disease comprising: exposing vascular peripheral tissue to a selected wave energy and performing Doppler analysis thereon in order to determine the nature of fluid flow in, or through, said vascular tissue whereby an indicator showing loss of reverse flow or loss of triphasic signal is indicative of disease in said limb. In a preferred method of invention the peripheral limb is a lower limb such as a foot and, more preferably still, the indicator is indicative of arterial disease in said limb.
It will be apparent to those skilled in the art that the said Doppler analysis can be undertaken in either a qualitative or quantitative fashion. In the former instance, visual interpretation of an image of a waveform, representing blood flow in said tissue i.e. an image showing forward and, if present, reverse flow, can be used to judge the nature of the flow in, or through, said vascular tissue.
Alternatively, or additionally, quantitative analysis of the said waveform may be undertaken. In this instance, at least one index of said waveform is analysed such as, without limitation, the pulsatility index, resistance index or specteral broadening index may be used.
Additionally or alternative, the following indices may be used. The monophasic, biphasic or triphasic profiles of said vascular tissue. Reference herein to monophasic, biphasic or triphasic profiles includes reference to the waveforms described in reference 13 wherein a monophasic profile (or waveform) is indicative of a single forward flow, a biphasic profile (or waveform) is indicative of 2 forward flows and a triphasic profile (or waveform) is indicative of a forward, reverse, forward flow. These waveforms are further illustrated in Figure 1.
In a preferred method of the invention said selected wave energy is ultrasound and most preferably at a frequency between 3 and 10 MHz and most typically at a frequency of between 5 and 8 MHz.
According to a further aspect of the invention there is provided an apparatus for use in determining peripheral limb disease wherein said device comprises: a Doppler waveform generating device which can be applied to a limb to be investigated, or held in close proximity thereto, in order to generate Doppler information relating to fluid flow in said limb; and a display device to which said Doppler waveform generating device is operationally coupled, said display device including an image generating device whereby visual images produced by said image generating device of waveforms produced by said Doppler generating device can be displayed for the purpose of enabling at least qualitative analysis thereof. According to a further aspect of the invention there is provided a device, most preferably a hand-held device, for use in determining peripheral limb disease, wherein said device comprises a hand held Doppler waveform device operationally coupled to a display device whereby visual images of waveforms produced by said device are displayed in conventional manner, on said display device for the purpose of enabling at least qualitative analysis thereof by a user.
According to a further aspect of the invention there is provided the new use of an existing peace of equipment wherein a hand-held Doppler analysis device can be routinely and reliably used in order to determine peripheral limb disease, and, more specifically, lower limb or foot disease in diabetes where more preferably, the device is used to determine arterial disease in diabetes.
Ideally this existing piece of equipment is operationally coupled to a display device or screen whereby at least a qualitative assessment of visual images representing waveforms of fluid flow in peripheral limbs can be made.
Without being limited to any scientific explanation, we believe that our methodology is a reliable predictor of peripheral limb disease because occlusions are detected by a lack of reverse flow following contraction of the heart, i.e. during the systolic phase.
An embodiment of the invention will now be described by way of example only with reference to the following figures wherein:
Figure 1 is a diagram showing the characteristics of monophasic, biphasic and triphasic flow patterns through peripheral limb tissue;
Figure 2 represents a chart showing the ABPI index for a variety of subjects. Horizontal lines represent ABPI values of 1.15 and 0.9. V represents the control subjects with arterial disease; D represents diabetics; DN represents diabetics with neuropathy; C represents control subjects; DV represents diabetics with arterial disease; DNV represents diabetics with neuropathy and arterial disease;
Figure 3 shows the ABPI and TBI indices for a variety of subjects. Horizontal lines represent an ABPI value of 0.9 and a TBI value of 0.75. V represents control subjects with arterial disease; D represents diabetics; DN represents diabetics with neuropathy; C represents control subjects; DV represents diabetics with arterial disease; DNV represents diabetics with neuropathy and arterial disease. Figure 4 is a diagrammatic representation of a hand held Doppler device adapted for use in accordance with the invention. Parameters for the investigation
The following investigation was undertaken by making a comparison with the, conventionally used, gold standard non-invasive assessment, CDI. It was estimated that analysis of 120 limbs would be required to facilitate valid comparisons of the efficacy of the modalities in individuals with and without arterial disease based on pragmatic factors related to feasibility of recruitment, study duration and participant burden. The study was given ethical approval by the local ethics committee and all subjects gave written informed consent.
Research Design and Methods
No individuals had active foot disease, rest pain or signs suggestive of lower limb critical ischaemia. Individuals without diabetes, with and without arterial disease were used as controls. Patients with Types 1 and 2 diabetes were confirmed as having diabetes in their medical records. Subjects were grouped according to the presence or absence of diabetes, peripheral neuropathy and peripheral vascular disease on CDI. Neuropathy was tested using 10g monofilament, 128Hz tuning fork and proprioception at the 1st Metatarsophalangeal joint, using ICDF guidelines. Loss of sensation of any modality was indicative of peripheral neuropathy.
The study was performed over a period of eight months. All tests were performed at one visit. All individuals had capillary blood sugar measurements and arterial CDI performed at the end of each attendance.
Exclusion criteria included smoking, other causes of peripheral neuropathy, history of reconstructive vascular surgery, other causes of peripheral vascular disease, skin changes associated with venous disease, pyrexia and significant cardiorespiratory and/or renal disease. All patients (with
two exceptions of serum creatinine ~0.3mmo1/1), had serum creatinine less than 0.2mmo1/1 and haemoglobin values no lower than 11 g/d 1.
Room temperature was maintained at 240C to 25°C. Individuals were rested reclining at approximately 20 degrees to the horizontal and acclimatised for 20 minutes. Foot skin temperatures were measured until a steady state was achieved.
Foot pulses of individuals with diabetes and/or peripheral vascular disease were palpated by at least two examiners and classified as present or absent. Absence of one or both foot pulses was used as an indicator of arterial disease. Toe pressures were measured by the photplethysmographic (PPG) method, employing an infrared sensor placed on the hallux, (Dopplex Assist,
Huntleigh Healthcare, Cardiff, UK). Both brachial pressures were measured using PPG and hand held Doppler (Huntleigh Heathcare, Cardiff, UK), the higher value used in calculating the ABPI and TBI. Toe pressures were taken at three, five-minute intervals and a mean calculated. Ankle pressures were then measured using PPG and hand-held Doppler. ABPI values <0.9 and TBI <0.75 were used as indicators of significant Peripheral Arterial Occlusive Disease (PAOD). Both qualitative and quantitative Doppler waveform analysis was performed on the dorsalis pedis and posterior tibial arteries using the Dopplex Assist, employing an 8MHz Doppler probe. Qualitative waveform analysis was performed by visual interpretation of displayed waveforms. Loss of reverse flow
(loss of triphasic signal) was used as an indicator of significant arterial disease. Quantitative waveform analyses were performed simultaneously by the Dopplex Assist. Three indices, the pulsatility index, resistance index (Pourcelot) and spectral broadening index were recorded for each artery. CDI was performed at the end of each session using a Toshiba SSH- 140A ultra-sound system (Toshiba Medical Systems, Crawley, UK) with two probes, a 5-MHz linear array probe (PLF-503NT), and a 3.75-MHz curvilinear probe (PVF-375MT). All individuals were scanned from the common femoral artery to the distal third of the tibial and peroneal arteries. Arterial disease on
CDI was deemed significant when occlusions, single or multiple stenoses, or diffuse stenotic disease in the femoropopliteal segments, individually or collectively, caused significant velocity change and flow disturbance locally and resulted in loss of reverse flow distally. Occlusions of below-knee arteries were also recorded. Quality control was assured by acquiring a second CDI scan of
10 individuals with and without arterial disease within 1 month of the original scan. The repeat scan was performed by medical physicists at the local teaching hospital. Statistical analysis was performed using SPSS version 10 software (Chiacgo, IL). Results
Demographics
A total of 130 limbs were studied on 68 volunteer subjects. All subjects were white Caucasian, predominantly male (74%) in the diabetes groups. The groups were matched for age (F5, 74=0.783, p=0.565), with means ranging from 63 to 69 years, and body mass index (F5, 74=2.04, p-
0.083). All groups with diabetes had mean body mass indices greater than 25, the group with neuropathy greater than 30. Type 2 diabetes accounted for 85% of the total number of subjects with diabetes and was evenly distributed through all groups except group five. Duration of diabetes was similar for all groups (F3, 52=2.08, p=0.115), with means ranging from 11 to 24 years. Repeat CDI demonstrated complete agreement on the presence or absence of significant arterial disease. The strong association between detectable peripheral neuropathy and arterial disease meant that group five (arterial disease but no neuropathy) was relatively small and contained the limbs of individuals with type
2 diabetes only.
Foot pulses
The absence of one or more pulses was common in all groups, making this test prone to a high false positive rate and poor specificity. Both foot pulses were palpable in some individuals with significant arterial disease. In the groups with arterial disease, the absence of one or more pulses in the control group was a more sensitive test than in the groups with diabetes, where almost 20% of limbs had both pulses present.
Ankle brachial pressure index There was a strong positive correlation between Doppler and PPG ankle pressure measurement, (n=125, r=0.954, PO.001), Hand-held Doppler consistently gave marginally higher readings.
In the control groups, all limbs without arterial disease had ABPI values
>0.9 Employing Doppler, four of fourteen limbs with arterial disease had values >0.9 (29% false negative rate). Employing PPG, only two values were >0.9
(14% false negative rate).
In the presence of diabetes, there were several ABPI values >1.3, in individuals with and without arterial disease (Figure 1). Three limbs with no arterial disease had values >0.9. Using Doppler, twelve out of 23 limbs with significant arterial disease had ABPI values >0.9 (53% false negative rate). Employing PPG reduced the false negative rate to 32%. There was an association between elevated ABPI values and neuropathy. Mean ABPI values in limbs with no arterial disease but detectable peripheral neuropathy were higher than those with no neuropathy (1.21 vs. 1.06 t= 2.39, df=64, p=0.02).
All seven ABPI values >0.9 identified in the groups with diabetes and arterial disease were associated with detectable peripheral neuropathy. This reflected in a false negative rate and poor sensitivity (Table 2). No values >0.9 were identified in those with arterial disease but no neuropathy using PPG. Using ICDF guidelines on ABPI measurement, limiting the upper range to 1.15, would still have resulted in a false negative rate of 6 of 16 (38%) employing Doppler and 5 of 15 (33%) employing PPG, in the group with peripheral neuropathy and arterial disease. Toe brachial pressure index Comparatively lower toe pressures reflected in TBI values that were universally lower than ABPI values across all groups (t=10.7, df=123, p<0.001). TBI did reflect the presence of arterial disease in all groups (F5, 121=13.56, p<0.001 ; Figure 2).
In individuals with diabetes and arterial disease, there were 15 limbs with neuropathy vs. 7 without. Mean TBI values were 0.49 and 0.58 respectively
(t=1.32, df=20, p=0.27). In the groups with no arterial disease, there 41 limbs with neuropathy and 25 without. Mean TBI values were 0.85 and 0.82 respectively (t=0.438, df=64, p=0.628). These results demonstrated that peripheral neuropathy did not influence TBI values in this study. In the control group, TBI identified all 13 limbs with arterial disease, but 5 of 21 control limbs with no disease had values <0.75 (Table 2.)
Of the 22 limbs in the groups with diabetes and arterial disease, but 5 or 21 control limbs with no disease had values <0.75 (Table 2.) Of the 22 limbs in the groups with diabetes and arterial disease, only 2 false negatives were identified (10%). Analysis of the 66 limbs of individuals with diabetes but no arterial disease, demonstrated 23 false positive results (35%).
Continuous waveform analysis Qualitative waveform analysis
Two from 14 control limbs with arterial disease had triphasic profiles in both foot vessels, (false negative rate=15%). One of the two limbs had a monophasic signal in one tibial vessel on CDI and no proximal disease. Of 27 limbs in the control group with no arterial disease, one had an absent flow in a single vessel (false positive rate=4%).
In diabetes, of those limbs with no detectable peripheral neuropathy or arterial disease (n=25 limbs), two limbs had absent flow in a single vessel. Where flow was detected, all signals were triphasic (false positive=8%). However, in those limbs with no arterial disease but detectable peripheral neuropathy (n=41 limbs), 12 limbs had at least one waveform with loss of reverse flow and two had undetectable flows (False positive rate=34%). In the presence of arterial disease, there was a zero false negative rate when any vessel waveform anomaly was regarded as indicative of the presence of arterial disease in the absence of neuropathy (n=7). Where neuropathy was present (n=16), one limb had two triphasic signals, but had diffuse atherosclerotic disease on CDI (False negative rate of 6%). Quantitative waveform analysis
Generally, the Resistance Index was the more accurate indicator of arterial disease than the Pulsatility or Spectral Broadening Indices. However, this modality's major limitation in this study was its inability to perform accurate analyses in the presence of low amplitude and/or low intensity signals, often allocating normal index values to qualitatively abnormal waveforms. This was most evident in the group with diabetes and arterial disease, where 14 of 46 analyses (30%) were erroneous.
Conclusions
In the clinical assessment of lower limbs for arterial disease, palpation of foot pulses is mandatory. However, the test is subjective and is influenced by many factors (12). In our assessment, the absence of one or both foot pulses was found to be a sensitive test in individuals without diabetes. In subjects with diabetes, its sensitivity was reduced, detecting four out of five limbs with arterial disease in the presence of detectable peripheral neuropathy. However, the frequent absence of one or both foot pulses in subjects with no arterial disease resulted in a notable loss of specificity the poor specificity of foot pulses in diabetes reduced its overall accuracy.
ABPI accurately reflected underlying arterial disease in the limbs of individuals without diabetes and those with diabetes but no detectable peripheral neuropathy. However, a mean ABPI >0.9 in the group with arterial disease and detectable peripheral neuropathy reflected a considerable loss of sensitivity. ABPI demonstrated the highest specificity and positive predictor value of all the tests across all groups (Table 2), low values being highly indicative of arterial disease. However, this inability to detect arterial disease in the presence of detectable peripheral neuropathy resulted in false negative results in 1/3 of limbs. This finding is probably due to the influence of arterial calcification. ABPI was less sensitive than palpation of foot pulses in screening for arterial disease in diabetes in the presence of detectable peripheral neuropathy.
TBI did not improve on the screening offered by pulses and ABPI in limbs without neuropathy, but was superior to ABPI in screening for arterial disease in limbs with neuropathy, with a normal TBI effectively excluding the presence of significant arterial disease in limbs with neuropathy. TBI maintained its sensitivity through all the diabetes groups. Its specificity did however reduce in the presence of peripheral neuropathy and this reflected in a reduced accuracy (Table 2). TBI was demonstrated to be an effective screening tool in diabetes, both in limbs with and without detectable peripheral neuropathy and appears therefore to be less influenced by arterial calcification than ABPI.
Qualitative waveform analysis in diabetes was as sensitive and specific in limbs without detectable neuropathy as pulses and ABPI. The modality as as sensitive as TBI in the presence of detectable peripheral neuropathy. Although specificity was reduced in diabetes, this was less than that demonstrated by TBI.
The presence of a triphasic waveform with reverse flow in both foot arteries was demonstrated to effectively exclude significant arterial disease in over 90% of limbs with neuropathy. Monophasic or biphasic flow (with loss of reverse flow) in either foot artery was highly suggestive of haemodynamically significant arterial disease.
Quantitative waveform analysis in this study was a very poor screening modality. The high frequency of erroneous results demonstrated on our equipment excludes it as a screening tool. Further analysis of the 14 limbs that had no arterial disease on CDI but loss of reverse flow in one foot artery on qualitative waveform analysis, demonstrated that all but one occurred in the presence of detectable peripheral neuropathy. These limbs also had reduced TBI (r=0.409, p=0.008) and absent foot pulses (r=0.495, p<0.001), suggesting that CDI may have been less sensitive than waveform analysis and TBI in detecting significant arterial disease in these individuals.
Qualitative waveform analysis was the most effective screening tool of all the methods tested in this study. In the absence of neuropathy it performed as well as ABPI and pulses, but in neuropathic limbs was clearly superior to pulses and ABPI with comparable sensitivity and marginally better specificity than TBI.
Our findings demonstrate that in screening for lower limb arterial disease in diabetes, qualitative waveform analysis is preferred.
Accordingly, Figure 4 shows a representation of a hand held Doppler device for use in the method of the invention. The device comprises a Doppler Probe 1 , of conventional nature, which is operationally and releasably coupled to an audio/visual display means 2. Display means 2 comprises a screen 3 and speaker 4. Waveforms indicative of fluid or blood flow in tissue under examination are represented, in conventional manner and using conventional equipment, on screen 3 +/or via sounds emanating from speaker 4. A user of the equipment is therefore able to use Doppler Probe 1 to visualise blood flow in selected tissue and using conventional skill and judgement perform a qualitative analysis of the images +/or sounds presented on screen 3 or emanating from speaker 4. In this way the invention can be straight forwardly practised by those skilled in the art with a view to efficiently and reliably diagnosing vascular disease, particularly in lower limbs.
Table 1. Group distribution and characteristics
Figure imgf000017_0001
Table 2. Validation table - all groups. ABPI measured using hand held Doppler.
Figure imgf000017_0002
References
1. Van Houtum WH, Lavery LA, Harkless LB, The impact of diabetes-related lower-extremity amputations in The Netherlands. J Diabetes Complications 10:325-330, 1996.
2. Marinelli MR, Beach KW, Glass MJ, Primozich JF, Strandness DE Jr: Noninvasive testing vs clinical evaluation of arterial disease. A prospective study. JAMA 241 :2031-2034, 1979
3. Faglia E, Favales F, Quarantiello A, Calia P, Clelia P, Brambilla G1
Rampoldi A, Morabito A; Angigraphic evaluation of peripheral arterial occlusive disease and its role as a prognostic determinant for major amputation in diabetic subjects with foot ulcers. Diabetes Care 21 : 625-630, 1998.
4. European Working Group on critical leg ischaemia; Second European consensus document on chronic critical leg ischaemia. Eur J Vase Surg (Supp A):1-32, 1992.
5. Goebel FD, Fuessl HS.Monckeberg's sclerosis after sympathetic denervation in diabetic and non-diabetic subjects. Diabetolgia 24:347-350,1983.
6. Apelqvist J, Bakker K, van Houtum WH, Nabuurs-Franssen MH, Schaper NC: International consensus and practical guidelines on the management and the prevention of the diabetic foot. International working groups on the diabetic foot. Diabetes Metab Res Rev 16 (Suppl 1):S84-92, 2000
7. Uccioli L, Monticone G, Durola L, Russo F, Mormile F, Mennun G, Mensinger G: Autonomic neuropathy influences great toe blood pressure. Diabetes Care 17:284-287, 1994
8. Chew JT, Tan SB, Sivathasan C, Pavanni R, Tan SK: Vascular assessment in the neuropathic diabetic foot. Clin Orthop Relat Res 320:95-100, 1995
9. Stevens MJ, Goss DE, Foster AV, Pitei D, Edmonds ME, Watkins PJ: Abnormal digital measurements in diabetic neuropathic foot ulceration. Diabet Med 10:909-915, 1993.
10. Toursarkissian B, Mejia A, Smilanich RP, Schoolfield J, Shireman PK,
Sykes MT: Noninvasive localization on infrainguinal arterial occlusive disease in diabetics. Ann Vase Surg 15:73-78, 2001.
11. Brooks B, Dean R, Patel S, Wu B, Molyneaux L, Yue DK: TBI or not TBI: that is the question. Is it better to measure toe pressure than ankle pressure in diabetic patients? Diabet Med 18:528-532, 2001.
12. Moneta GL, Yeager RA, Antonovic R, Hall LD, Caster JD, Cummings CA, Porter JM: Accuracy of lower extremity arterial duplex mapping: J Vase Surg 15:275-284, 1992.
13. Shaalan WE, French-Sherry E, Castilla M, Lozanski L, Bassiouny HS: Reliability of common femoral artery hemodynamics in assessing the severity of aortoiliac inflow disease. J Vase Surg 37:960-969, 2003
14. Williams DT, Price P, Harding KG: The clinical evaluation of lower limb perfusion in diabetic foot disease. Br J Diabetes Vase Dis 3:394-398, 2003

Claims

1. A method for screening for peripheral limb disease comprising: a) exposing vascular peripheral tissue to a selected wave energy and performing Doppler analysis thereon in order to generate data indicative of the nature of fluid flow in, or through, said vascular tissue; b) examining said data for reverse flow or loss of triphasic signal; and c) where said loss of reverse flow or loss of triphasic signal is present concluding that there is disease in said limb.
2. A method according to claim 1 wherein part c) involves concluding that there is arterial disease in said limb.
3. A method according to claims 1 or 2 wherein the limb is a lower limb such as a foot.
4. A method according to any preceding claim wherein said Doppler analysis is undertaken in either a qualitative or a quantitative fashion.
5. A method according to claim 4 wherein said qualitative analysis involves visual interpretation of an image waveform wherein the waveform represents blood flow in said tissue.
6. A method according to claim 5 wherein said visual interpretation involves an image waveform that represents blood flow in said tissue and the waveform is fashioned to show either forward and/or reverse flow.
7. A method according to claim 4 wherein said analysis is quantitative and therefore at least one of the following indices are analysed in order to determine reverse flow or loss of triphasic signal; pulsatility index, resistance index or spectral broadening index.
8. A method according to claim 7 wherein, additionally or alternatively, the following indices are analysed: monophasic index, biphasic index or triphasic index.
9. A method according to any preceding claim wherein said selected wave energy comprises ultrasound at a frequency of between 3-10MHz.
10. An apparatus for use in determining peripheral limb disease wherein said device comprises: a Doppler waveform generating device which can be applied to a limb to be investigated, or held in close proximity thereto, in order to generate Doppler information relating to fluid flow in said limb; and a display device to which said Doppler waveform generating device is operationally coupled, said display device including an image generating device whereby visual images produced by said image generating device of waveforms produced by said Doppler generating device can be displayed for the purpose of enabling at least qualitative analysis thereof.
11. An apparatus according to claim 10 wherein said apparatus is hand held.
12. An apparatus according to claims 10 or 11 wherein an image analysis device is also provided for quantitatively analysing either said Doppler information or said waveforms in order to provide information on the fluid flow through said limb.
13. An apparatus according to claims 10 to 12 wherein said device provides visual or quantitative data indicative of any loss of reverse flow or triphasic signal.
14. The use of a Doppler waveform device to determine peripheral limb disease.
15. Use according to claim 14 wherein said device is used to determine arterial disease in diabetic limbs.
16. Use according to claim 15 wherein said limb is a foot.
17. A method for screening for peripheral limb disease as substantially herein described.
18. A device for determining the existence of peripheral limb disease as substantially herein described.
19. The use of a Doppler analysis device as substantially herein described.
PCT/GB2006/002626 2005-07-27 2006-07-14 Improvements relating to the detection of lower limb disease Ceased WO2007012809A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0515325A GB0515325D0 (en) 2005-07-27 2005-07-27 Improvements relating to the detection of lower limb disease
GB0515325.9 2005-07-27

Publications (2)

Publication Number Publication Date
WO2007012809A2 true WO2007012809A2 (en) 2007-02-01
WO2007012809A3 WO2007012809A3 (en) 2007-05-24

Family

ID=34976610

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/002626 Ceased WO2007012809A2 (en) 2005-07-27 2006-07-14 Improvements relating to the detection of lower limb disease

Country Status (2)

Country Link
GB (1) GB0515325D0 (en)
WO (1) WO2007012809A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019135096A1 (en) * 2018-01-02 2019-07-11 Bluedop Medical, Ltd. System for determining peripheral artery disease and method of use
US10966617B2 (en) 2009-03-13 2021-04-06 Bluedop Medical Ltd. Haemodynamic data estimation
US11660063B2 (en) 2015-11-18 2023-05-30 Bluedop Medical, Ltd. System for determining peripheral artery disease and method of use
US11678808B2 (en) 2009-03-13 2023-06-20 Bluedop Medical, Ltd. Haemodynamic data estimation apparatus and method of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950611A0 (en) * 2002-08-06 2002-09-12 Uscom Pty Ltd Blood flow analysis system
EP1486169A3 (en) * 2003-06-13 2005-01-12 Brensing, Andreas Device for the acoustic examination of the heart of a patient

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10966617B2 (en) 2009-03-13 2021-04-06 Bluedop Medical Ltd. Haemodynamic data estimation
US11678808B2 (en) 2009-03-13 2023-06-20 Bluedop Medical, Ltd. Haemodynamic data estimation apparatus and method of use
US12611111B2 (en) 2009-03-13 2026-04-28 Bluedop Medical, Ltd. Haemodynamic data estimation apparatus and method of use
US11660063B2 (en) 2015-11-18 2023-05-30 Bluedop Medical, Ltd. System for determining peripheral artery disease and method of use
US12245885B2 (en) 2015-11-18 2025-03-11 Bluedop Medical, Ltd. System for determining peripheral artery disease and method of use
WO2019135096A1 (en) * 2018-01-02 2019-07-11 Bluedop Medical, Ltd. System for determining peripheral artery disease and method of use
US11607198B2 (en) 2018-01-02 2023-03-21 Bluedop Medical, Ltd. System for determining peripheral artery disease and method of use
EP4434470A3 (en) * 2018-01-02 2024-11-20 BlueDop Medical, Ltd. System for determining peripheral artery disease and method of use

Also Published As

Publication number Publication date
GB0515325D0 (en) 2005-08-31
WO2007012809A3 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
Vriens et al. Clinical examination and non‐invasive screening tests in the diagnosis of peripheral artery disease in people with diabetes‐related foot ulceration
Williams et al. An evaluation of the efficacy of methods used in screening for lower-limb arterial disease in diabetes
Sarin et al. Duplex ultrasonography for assessment of venous valvular function of the lower limb
Tehan et al. Non-invasive vascular assessment in the foot with diabetes: sensitivity and specificity of the ankle brachial index, toe brachial index and continuous wave Doppler for detecting peripheral arterial disease
Stein et al. Limitation of the resting ankle-brachial index in symptomatic patients with peripheral arterial disease
Nicolaï et al. Ankle brachial index measurement in primary care: are we doing it right?
Matsumoto et al. Associations of brachial-ankle pulse wave velocity and carotid atherosclerotic lesions with silent cerebral lesions
Sarin et al. Photoplethysmography: a valuable noninvasive tool in the assessment of venous dysfunction?
Janani et al. Efficiency of new custom-made pulse oximeter sensor holder in assessment of actual pulp status
Azzopardi et al. Agreement of clinical tests for the diagnosis of peripheral arterial disease
Perrault et al. Establishing the interchangeability of arterial stiffness but not endothelial function parameters in healthy individuals
Sonter et al. Intratester and intertester reliability of toe pressure measurements in people with and without diabetes performed by podiatric physicians
Alagha et al. Diagnostic performance of ankle-brachial pressure index in lower extremity arterial disease
Huthart et al. Validation of a standardised duplex ultrasound classification system for the reporting and grading of peripheral arterial disease
Rose Noninvasive vascular laboratory for evaluation of peripheral arterial occlusive disease: Part II—Clinical applications: Chronic, usually atherosclerotic, lower extremity ischemia
CN117731326A (en) Automatic blood pressure monitoring method and system based on ultrasonic waves
CN112587170A (en) Intravascular plaque load detection method, system and terminal based on dual-mode imaging
Bonham et al. Are ankle and toe brachial indices (ABI-TBI) obtained by a pocket Doppler interchangeable with those obtained by standard laboratory equipment?
WO2007012809A2 (en) Improvements relating to the detection of lower limb disease
Järvisalo et al. Noninvasive assessment of brachial artery endothelial function with digital ultrasound and 13-MHz scanning frequency: feasibility of measuring the true inner luminal diameter using the intima-lumen interface
Hamel et al. Comparison of the automated oscillometric method with the gold standard Doppler ultrasound method to access the ankle-brachial pressure index
Davies et al. The utility of pulse volume waveforms in the identification of lower limb arterial insufficiency
Wong et al. Reliability of automated blood pressure devices used by hypertensive patients
Zou et al. Diagnostic accuracy of ultrasound in carpal tunnel syndrome: analysis of established and novel parameters
Lehmann et al. Aortic compliance measured by non-invasive Doppler ultrasound: application of a personal computer based Mk II system and its repeatability

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06764970

Country of ref document: EP

Kind code of ref document: A2